PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG studyAlejandra Martinez, Fabrice Lecuru, Nicolò Bizzarri, Cyrus Chargari, Anne Ducassou, Anna Fagotti, Francesco Fanfani, Giovanni Scambia, David Cibula, Berta Díaz-Feijoo, Antonio Gil Moreno, Martina Aida Angeles, Mustafa Zelal Muallem, Christhardt Kohler, Mathieu LuyckxSee the full list of authors
30 January 2023
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial programRAINBO Research Consortium
20 December 2022
Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)Faiza Gaba, Karen Ash, Oleg Blyuss, Nicolò Bizzarri, Paul Kamfwa, Pedro T Ramirez, Ioannis C Kotsopoulos, Dhivya Chandrasekaran, Nana Gomes, John Butler, Marielle Nobbenhuis, Thomas Ind, Owen Heath, Desmond Barton, Arjun JeyarajahSee the full list of authors
15 November 2022
A multimodal prehabilitation program for the reduction of post-operative complications after surgery in advanced ovarian cancer under an ERAS pathway: a randomized multicenter trial (SOPHIE)Berta Díaz-Feijoo, Nuria Agusti, Raquel Sebio, Marina Sisó, Núria Carreras-Dieguez, Santiago Domingo, Oscar Díaz-Cambronero, Aureli Torne, Graciela Martinez-Palli, Ma José Arguís
6 July 2022
CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16)David Cibula, Martina Borčinová, Roman Kocian, David Feltl, Sona Argalacsova, Pavel Dvorak, Daniela Fischerová, Pavel Dundr, Jiri Jarkovsky, Eva Höschlová, Jiri Slama, Giovanni Scambia
13 September 2022
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiationCarmen Garcia-Duran, Francisco Grau, Guillermo Villacampa, Ana Oaknin
20 April 2022
CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancerJean-Marc Classe, Gwennael Ferron, Lobna Ouldamer, Tristan Gauthier, Sheik Emambux, Laurence Gladieff, Pierre-Francois Dupre, Amélie Anota
23 March 2022
Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)Gabriella Macchia, Barbara Alicja Jereczek-Fossa, Roberta Lazzari, Annamaria Cerrotta, Francesco Deodato, Edy Ippolito, Cynthia Aristei, Maria Antonietta Gambacorta, Giovanni Scambia, Vincenzo Valentini, Gabriella Ferrandina
21 June 2021
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groupsClorinda Schettino, Lucia Musacchio, Michele Bartoletti, Paolo Chiodini, Laura Arenare, Gustavo Baldassarre, Daniela Califano, Ettore Capoluongo, Maria Paola Costi, Maurizio D'Incalci, Sergio Marchini, Delia Mezzanzanica, Nicola Normanno, Stefania Scala, Stefano GreggiSee the full list of authors
22 March 2022
Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial)Glauco Baiocchi, Carlos Eduardo Mattos Cunha Andrade, Reitan Ribeiro, Renato Moretti-Marques, Audrey Tieko Tsunoda, Vanessa Alvarenga-Bezerra, Andre Lopes, Ronaldo Lúcio Rangel Costa, Lillian Yuri Kumagai, Levon Badiglian-Filho, Carlos Chaves Faloppa, Henrique Mantoan, Louise De Brot, Ricardo Dos Reis, Bruna Tirapelli Goncalves
2 March 2022
